How many clinical trials are tracked for Movement Disorders?

8 trials are tracked, 0 with published results.

Movement Disorders Research

Movement Disorders: current evidence & treatments

Parkinson's disease (PD) is a complex movement disorder with multiple genetic, environmental, and mechanistic factors. Genetic studies have identified strong risk factors: heterozygous GBA1 L444P carriers have ninefold higher odds of PD compared to non-carriers (OR 9.19, 95% CI 6.94–12.16) ⁹, and bipolar disorder is associated with a 3.65-fold higher risk of PD (HR 3.65, 95% CI 2.16–6.17) ³. Six novel loci and nine recessive loci have been identified for young-onset PD in European ancestry ⁴. Additionally, a mitochondrial polygenic score is linked to alpha-synuclein seeding in LRRK2-related PD ¹⁷. Mechanistically, the exercise-microbiota-queuine-tRNA axis may influence mitochondrial function and proteostasis ¹, and RNA editing alterations are observed in PD patients, with distinct patterns between brain and peripheral blood ¹⁸. Ferroptosis-immune crosstalk is also implicated in CNS diseases including PD ²⁴.

Diagnostic and therapeutic advances have been reported. Quantitative susceptibility mapping MRI reveals distinct iron deposition patterns differentiating PD from atypical parkinsonian syndromes: substantia nigra susceptibility is increased in PD (SMD 1.24), putaminal susceptibility is higher in MSA, and pallidal susceptibility is higher in PSP ⁷. MRI volumetric differences are seen in PD patients with mild cognitive impairment versus cognitively normal PD ²⁵. For treatment, continuous subcutaneous foslevodopa/foscarbidopa improves off time in PD, with no significant between-group difference between prior DBS and no prior DBS groups ⁸. Deep brain stimulation (DBS) improves motor function and reduces levodopa needs regardless of GBA mutation status ¹⁶, and DBS modestly improves freezing of gait (FOG-Q MD -2.99) ²². Prasinezumab showed non-significant delay in motor progression versus placebo in early-stage PD ¹¹. GLP-1 agonists showed limited motor benefit but a small improvement in quality of life (PDQ-39 MD -0.75) ²¹. Acupuncture moderately improves sleep quality in PD (MD 14.52) ²³. Sensory cueing improves gait velocity (somatosensory MD 0.12 m/s, visual MD 0.11 m/s) and stride length (visual MD 11.46 cm) ¹⁵. Combined motor and cognitive therapy shows mixed benefits: sequential treatment improved balance but not functional mobility ¹². VR and physiotherapy are equally effective for balance ¹⁴.

Non-motor symptoms in PD are complex; current classifications inadequately reflect their interrelationship ². Tourette syndrome involves multilevel dysfunction linking internal states to motor output via negative reinforcement ¹⁰. Nocebo effects can be induced through negative verbal suggestion in chronic conditions including PD ²⁰. Nutrient and metabolite interventions for neurodegenerative diseases show inconsistent clinical translation ⁶. AI applications for protein misfolding diseases, including PD, are being explored ¹⁹. The HMC3 microglial model illuminates neurodegenerative mechanisms in PD ⁵. TCM metabolites show neuroprotective potential in zebrafish models ¹³.

GBA1 L444P carriers have ninefold higher odds of PD (OR 9.19) ⁹; bipolar disorder increases PD risk 3.65-fold ³.

QSM MRI differentiates PD from atypical parkinsonian syndromes via distinct iron deposition patterns ⁷.

Continuous subcutaneous foslevodopa/foscarbidopa improves off time in PD ⁸; DBS improves motor function and reduces levodopa needs regardless of GBA status ¹⁶.

Sensory cueing (somatosensory, visual, auditory) improves gait velocity and stride length in PD ¹⁵.

Acupuncture moderately improves sleep quality in PD (MD 14.52) ²³; GLP-1 agonists show limited motor benefit but small quality-of-life improvement ²¹.